Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study

References

• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–943. https://doi.org/10.1001/jamainternmed.2020.0994.
   PubMed Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–1643. https://doi.org/10.1038/s41591-020-1051-9.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen Y, Meng Z. Immunomodulation for severe COVID-19 pneumonia: the state of the art. Front Immunol. 2020;11:577442. https://doi.org/10.3389/fimmu.2020.577442.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384:693–704. https://doi.org/10.1056/NEJMoa2021436.
   PubMed Web of Science ®Google Scholar
• Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317–1329. https://doi.org/10.1001/jama.2020.17022.
   PubMed Web of Science ®Google Scholar
• Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1298–1306. https://doi.org/10.1001/jama.2020.16761.
   PubMed Web of Science ®Google Scholar
• Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307–1316. https://doi.org/10.1001/jama.2020.17021.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Misumi T, Izumi S, et al. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study. Sci Rep. 2021;11:10727. https://doi.org/10.1038/s41598-021-90246-y.
   PubMed Web of Science ®Google Scholar
• Jamaati H, Hashemian SM, Farzanegan B, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021;897:173947. https://doi.org/10.1016/j.ejphar.2021.173947.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang S, Dong X, et al. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Invest. 2020;130:6417–6428. https://doi.org/10.1172/JCI140617.
   PubMed Web of Science ®Google Scholar
• Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021;72:e373–e381. https://doi.org/10.1093/cid/ciaa1177.
   PubMed Web of Science ®Google Scholar
• WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–1341. https://doi.org/10.1001/jama.2020.17023.
   PubMed Web of Science ®Google Scholar
• Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Infect Dis Soc Am. 2021; Version 5.1.1. Available at https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Date last updated: September 3, 2021. Date last accessed September 7, 2021.
   Google Scholar
• World Health Organization. COVID-19 clinical management: living guidance, 25 January 2021. No.WHO/2019-nCoV/clinical/2021.1. World Health Organization,2021.15. Available at https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. Date last updated: January 25, 2021. Date last accessed September 7, 2021.
   Google Scholar
• COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Date last updated: September 3, 2021. Date last accessed September 7, 2021.
   Google Scholar
• WHO. COVID-19 weekly epidemiological update. World Heal Organ. 2021;(58):1–23. Available at https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---2-november-2021. Date last updated: November 2, 2021. Date last accessed November 5, 2021.
   Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239–1242. https://doi.org/10.1001/jama.2020.2648.
   PubMed Web of Science ®Google Scholar
• Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25:2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
   PubMedGoogle Scholar
• Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European respiratory society (ERS), European society of intensive Care Medicine (ESICM), European society of clinical microbiology and infectious diseases (ESCMID) and asociación latinoamericana del tórax (ALAT). Eur Respir J. 2017;50:1700582. https://doi.org/10.1183/13993003.00582-2017.
   PubMed Web of Science ®Google Scholar
• Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;49:1–45. https://doi.org/10.1086/599376.
   PubMed Web of Science ®Google Scholar
• Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21:e149–e162. https://doi.org/10.1016/S1473-3099(20)30847-1.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62:e1–e50. https://doi.org/10.1093/cid/civ933.
   PubMed Web of Science ®Google Scholar
• Goverment United Kingdom. World first coronavirus treatment approved for NHS use by government. Press Release June 16, 2020. Available at: https://www.gov.uk/government/news/world-first-coronavirus-treatment-approved-for-nhs-use-by-government. Date last updated: June 18, 2020. Date last accessed August 15, 2021.
   Google Scholar
• Olivas-Martínez A, Cárdenas-Fragoso JL, Jiménez JV, et al. In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. PLoS One. 2021;16:e0245772. https://doi.org/10.1371/journal.pone.0245772.
   PubMed Web of Science ®Google Scholar
• Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146:110–118. https://doi.org/10.1016/j.jaci.2020.04.006.
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. https://doi.org/10.1038/s41586-020-2521-4.
   PubMed Web of Science ®Google Scholar
• Chidambaram V, Tun NL, Haque WZ, et al. Factors associated with disease severity and mortality among patients with COVID-19: a systematic review and meta-analysis. PLoS One. 2020;15:e0241541. https://doi.org/10.1371/journal.pone.0241541.
   PubMed Web of Science ®Google Scholar
• Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with covid-19 pneumonia. N Engl J Med. 2021;384:20–30. https://doi.org/10.1056/NEJMoa2030340.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. https://doi.org/10.1016/S0140-6736(21)00676-0.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe covid-19 pneumonia. N Engl J Med. 2021;384:1503–1516. https://doi.org/10.1056/NEJMoa2028700.
   PubMed Web of Science ®Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med. 2020;383:2333–2344. https://doi.org/10.1056/NEJMoa2028836.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020;383:2030–2040. https://doi.org/10.1056/NEJMoa2022926.
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med. 2020;383:2041–2052. https://doi.org/10.1056/NEJMoa2019014.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020;323:2493–2502. https://doi.org/10.1001/jama.2020.8630.
   PubMed Web of Science ®Google Scholar
• Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med. 2021;9: S2213-2600(21)00263-0. https://doi.org/10.1016/S2213-2600(21)00263-0.
   PubMed Web of Science ®Google Scholar
• Lozano-Cruz OA, Jiménez JV, Olivas-Martinez A, et al. Adverse effects associated with the use of antimalarials during the COVID-19 pandemic in a tertiary care center in Mexico city. Front Pharmacol. 2021;12:668678. https://doi.org/10.3389/fphar.2021.668678.
   PubMed Web of Science ®Google Scholar
• Smith L, Karaba SM, Amoah J, et al. Hospital-acquired infections among adult patients admitted for coronavirus disease 2019 (COVID-19). Infect Control Hosp Epidemiol. 2021: 1–4. https://doi.org/10.1017/ice.2021.148.
   PubMedGoogle Scholar
• Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63:655–670. https://doi.org/10.4187/respcare.06314.
   PubMed Web of Science ®Google Scholar
• Grasselli G, Scaravilli V, Mangioni D, et al. Hospital-acquired infections in critically ill patients with COVID-19. Chest. 2021;160:454–465. https://doi.org/10.1016/j.chest.2021.04.002.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27:83–88. https://doi.org/10.1016/j.cmi.2020.07.041.
   PubMed Web of Science ®Google Scholar
• Peña JE, Rascón-Pacheco RA, Ascencio-Montiel IJ, et al. Hypertension, diabetes and obesity, major risk factors for death in patients with COVID-19 in Mexico. Arch Med Res. 2021;52:443–449. https://doi.org/10.1016/j.arcmed.2020.12.002.
   PubMed Web of Science ®Google Scholar
• Alcalde-Rabanal JE, Orozco-Núñez E, Espinosa-Henao OE, et al. The complex scenario of obesity, diabetes and hypertension in the area of influence of primary healthcare facilities in Mexico. PLoS One. 2018;13:e0187028, https://doi.org/10.1371/journal.pone.0187028.
   PubMed Web of Science ®Google Scholar